VTVT - vTv Therapeutics Inc logo

vTv Therapeutics Inc

VTVT

vTv Therapeutics Inc. develops oral small molecule drug candidates aimed at treating diabetes and other chronic diseases. Its lead candidate, cadisegliatin, is an investigational glucokinase activator for type 1 diabetes, currently in Phase III trials.

โš•๏ธ Healthcare NASDAQ Listed 2015 $ USD
$1,000 invested 10 years ago โ†’$94today

Score Overview

1 Year
Scoreโ€”
Net Growth82.37%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score4.9
Net Growth63.38%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth9x
Rev Trend33%
Revenue Consistencyโ€”
10 Years
Score
Net Growth70.91%
Net Trend50%
Net Income Consistency
Rev Growth58x
Rev Trend38%
Revenue Consistency
All Time
Score
Net Growth82.70%
Net Trend55%
Net Income Consistency
Rev Growth70x
Rev Trend44%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where vTv Therapeutics Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. VTVT does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 25.55โ€”
1 Year2025-10-23
$ 20.8422.60%
5 Years2021-10-22
$ 56.00-54.37%
10 Years2016-10-21
$ 272.40-90.62%
All Time2015-07-30
$ 435.60-94.13%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 36M-$ 4M$ 86M
2025$ 0.00-$ 26M$ 88M
2024$ 1M-$ 18M$ 36M
2023-$ 20M$ 9M
2022$ 2M-$ 19M$ 12M
2021$ 4M-$ 12M$ 13M
2020$ 6M-$ 8M$ 5M
2019$ 2M-$ 21M$ 1M
2018$ 12M-$ 7M$ 1M
2017$ 291K-$ 16M$ 11M
2016$ 634K-$ 16M$ 51M
IPO2015$ 519K-$ 27M$ 88M
VTVT - vTv Therapeutics Inc logo

vTv Therapeutics Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 6M to $ 0.00 and net income went from -$ 8M to -$ 26M. Revenue increased in 2 of those 5 years; net income in 2.

Across vTv Therapeutics Inc's full reported history, from 2015 to 2025, revenue declined from $ 519K to $ 0.00 and net income went from -$ 27M to -$ 26M. Revenue increased in 44% of the years measured; net income in 55%.

vTv Therapeutics Inc currently holds a 5-year HDB Score of 4.9 out of 10. How the HDB Score is calculated.

Membership

Explore VTVT with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies